Pacira BioSciences posted 2025 revenue of $726 million, up 4% year over year, with a record fourth quarter for Exparel as volumes rose 7% and net product sales increased 5%. The company issued 2026 guidance calling for total revenue of $745–$770 million and Exparel sales of $600–$620 million, and moved to extend its geographic footprint through an exclusive partnership with LG Chem to commercialize Exparel in select Asia-Pacific markets, with initial regulatory filings planned in South Korea and Thailand in 2026. Pacira also returned $150 million to shareholders via repurchases in 2025 and ended the year with $238 million in cash and $372 million in long-term debt.
The strategic question is whether Pacira can turn reimbursement tailwinds and international expansion into durable volume growth fast enough to offset pricing pressure and looming competition in liposomal bupivacaine. Exparel remains the franchise engine at $575 million in 2025 sales, supported by expanded indications and improving access dynamics, and Pacira points to strengthened intellectual property protection into the 2040s and recent litigation wins. Yet adjusted EBITDA declined to $186 million from $224 million in 2024 and non-GAAP net income fell to $122 million, reflecting higher R&D and SG&A as the company invests behind clinical programs, business development, and franchise defense.
For payers and health systems, the calculus is shifting toward non-opioid perioperative pathways as separate or add-on payments in ambulatory settings and value-based procurement models increasingly reward opioid-sparing outcomes. Demonstrating consistent reductions in opioid use and downstream adverse events—paired with procedure-level economic models—will be essential to securing formulary durability as hospitals scrutinize premium anesthetics. For surgeons and anesthesiologists, Exparel’s growth is tied to block-specific data, technique standardization, and workflow integration across infiltration and fascial plane blocks. Medical Affairs will need to scale education and real-world evidence that links analgesic performance to faster recovery, fewer complications, and lower total cost of care in diverse surgical populations.
Competitively, the message is that perioperative non-opioid analgesia remains investable despite generic signals. Pacira is reinforcing its lead through access strategy, KOL networks, and geographic partnerships rather than building costly ex-US infrastructure, a pattern echoed across specialty pharma seeking capital-efficient globalization. At the portfolio level, Zilretta was essentially flat at $117 million amid payer management of intra-articular steroids, while iovera grew 6% to $24 million, underscoring that device-enabled analgesia can complement drug-based protocols. Pipeline moves—the in-licensing of PCRX-2002 and advancement of PCRX-201, a locally administered gene therapy for knee osteoarthritis now in Phase 2—push Pacira into musculoskeletal disease modification where payers will demand rigorous long-term function and safety data.
The next 12–18 months will test whether Pacira can translate policy and procedural momentum into sustained share gains before price erosion accelerates. Watch for proof that Exparel’s growth persists as outpatient volumes migrate, that Asia-Pacific filings convert to commercial traction without margin dilution, and that early gene therapy and localized biologic data create a credible second growth engine. If Pacira can bind reimbursement, clinical evidence, and global partnering into a coherent operating model, non-opioid pain management could move from a single-product story to a defensible, multi-platform franchise.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
